A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
Willing and able to give consent/assent; if under the age of 18, guardian(s) is(are) willing and able to give consent.
Patients who received treatment with prademagene zamikeracel in the post-marketing setting.
You may not be if
Inability to properly follow the protocol as determined by the Principal Investigator (PI).
Clareo Health | A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
